Articles On Immutep (ASX:IMM)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Optiscan strives for ‘live biopsies’ for head and neck cancers LTR Pharma wins ethics clearance for fresh erectile dysfunction trial Noxopharm’s quest to cure lupus inches a step further Optiscan (ASX:OIL) will launch an imaging study of...

ASX burns through 118 points or 1.36% Energy only sector in green after crude oil gains Broad retreat after three straight weeks of losses   ASX falls three weeks in a row It was a day of bloodletting on the ASX 200 today, plummeting 118...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Poor Chinese relations, Covid, war and US tariffs prove too much for device maker Uscom The Mayne Health takeover deal isn’t over, but the prognosis is dire Bioxyne strikes medical cannabis vape import deal   Uscom bows out Uscom (ASX:UCM...

Highlights Key Australian companies witnessed notable market attention this week. Resource, retail, and healthcare sectors emerged in focus across the ASX stock market. Broader ASX 200 sentiment reflects shifting investor in...

ASX closes at new high of 9094 points, up 0.7pc Broad momentum across sectors with 10 of 11 higher US-Australian critical mineral deals fuel more resource stock gains   ASX roars to new highs on US-Australia rare earths deal The ASX 200 s...

S&P/ASX 300 Index (ASX: XKO) healthcare share Immutep Ltd (ASX: IMM) is marching higher today. Shares in the clinical-stage biotech company closed on Friday trading for 30.5 cents. In morning trade on Monday, shares are changing hands f...

Highlights Duratec and Lovisa identified among undervalued Australian equities. Broader ASX landscape shows resilience amid market diversity. Infrastructure, retail, and technology sectors feature strong value cases. A...

Highlights Australian market steadies amid global shifts. Emerging undervalued companies gain investor attention. Technology and healthcare sectors lead potential recovery. Australian equities spotlight undervalued opp...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin A summary of the highlights from Broker Call Extra updates throughout the week past....

Highlights Australian tech sector shows resilience across biotechnology and software Key players such as (ASX:IMM), (ASX:NXL) and (ASX:TNE) driving sector momentum Focus on research, innovation, and global scalability shapin...

Biotechnology stocks can be high-risk but also high-reward. The key is latching on to one with a promising product pipeline and the ability to bring it to market. Wilsons Advisory's healthcare analysts believe Immutep Ltd (ASX: IMM) may...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

  Highlights Banks including (ASX:ANZ), (ASX:NAB) and (ASX:WBC) remained firm within the asx 200 Real estate majors such as (ASX:CHC), (ASX:SCG) and (ASX:SGP) advanced across sessions Uptrend and downtrend scans reflected c...

  Highlights Recent trading activity reflects increased appetite for high-risk equity positions Market sentiment appears aligned with speculative trends seen in previous cycles Volatility remains a concern as investor focus...

  Highlights Spotlight on selected small-cap movements from the ASX board Sectoral shifts driving attention toward lesser-known equities Strategic interest emerges around companies diversifying portfolios asx 200 comp...

 Audeara and Ear Science Institute Australia will strive to develop a more affordable bone-conduction hearing device Auditor voices “substantial doubt” over Universal Biosensors’ viability Freeze a jolly good fellow: Brent Owens take over...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Highlights: ASX 200 trims early losses as sectors rebound Viva Energy under pressure after first-half update Lithium and uranium stocks show mixed reactions The ASX 200 began Tuesday’s session in the red, touching earl...

Highlights Fortescue delivers strong Q4 shipment results Healthcare stocks shine despite market weakness Bapcor tumbles after weak trading update The ASX 200 ended the session in negative territory, weighed down by wid...

ASX falls 0.31pc with 10 of 11 sectors down Healthcare moves against the grain, up 1.04pc Fortescue jumps 4.34pc on quarterly results ASX looking poorly by end of trade The ASX 200 stumbled a little today, down 0.31% with 10 of 11 sector...

On Friday the 13th of December last year, Percheron Therapeutics (ASX:PER)  CEO Dr James Garner awaited the top-line results of the phase IIb Duchenne muscular dystrophy trial from his Brisbane lounge room. The company’s clinical developmen...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

UBS reckons healthcare will fare better than any other ASX sector Bell Potter says Monash IVF has fertile recovery prospects Telix wins FDA usage expansion for prostate cancer imaging     Financial giant UBS has declared that enough is e...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

 Having produced more positive diagnostics results, Proteomics plans to launch its Promarker Endo device locally this year Immutep posts more positive trial results, this time for soft tissue sarcoma Broker values EBR Systems share price a...

Highlights Life360 (360), Codan Limited (CDA) and Immutep Limited (IMM) report robust revenue and margin expansion Technology sector advances on benchmarks tracked by the ASX 200, S&P/ASX All Technology Index Operational...

ASX posts 0.22pc gains, recovering from dip earlier in the day Xero brings big profit and revenue gains in quarterly report, lifting stock 4.7pc Insurance Australia surges 5.7pc on Royal Automobile Club of Western Australia deal   It was...

Late-stage biotechnology specialist Immutep (ASX: IMM) has achieved significant improvement in response rates compared to historical controls in a trial evaluating its first-line non-small cell lung cancer (NSCLC) treatment candidate. The a...

Amplia says it has reached the requisite level of ‘partial responders’ in its mid-stage pancreatic cancer study Immutep reports “remarkable” response rates in a German-based lung cancer trial Paradigm wins US ethics approval for knee osteo...

Immutep Ltd (ASX: IMM) shares are catching the eye on Thursday. In morning trade, the ASX 300 stock is up 11% to 31 cents. Why is this ASX 300 stock rocketing? Investors have been bidding the late-stage immunotherapy company's shares higher...

Highlights ERW reports high-grade silver surface samples using XRF analysis IMM involved in cancer treatment research combining multiple therapies LLC explores international development projects with UK-based Crown Estate...

The ASX200 is set to open nearly three quarters of a percent lower today (-0.41%), echoing a mixed performance on Wall Street. Listen to the HotCopper podcast for in-depth discussions and insights on all thebiggest headlines from through...

Highlights ASX 200 saw mixed sector performance with Energy and Real Estate leading gains. Immutep (IMM) and Carnegie Clean Energy (CCE) featured in Health and Energy developments. Declines recorded by Platinum Asset Managem...

Highlights Gold miners led gains as the ASX All Ords Gold index advanced, lifting the broader materials space Energy and tech sectors showed strength, defying broader market softness Small cap momentum driven by copper and g...

The ASX200 closed slightly down 0.08% at 8,151 points. Energy and Real Estate were the best performing sectors, up 0.8%, followed by Materials, Utilities, Telecommunication and Discretionary – all up around 0.6%. Health Care was the w...

ASX Gold Index leads gains, up more than 4pc Energy sector in the green despite 2pc oil price fall Tech index bucks Nasdaq’s trend to rise 0.8pc   It’s been a rollercoaster of a day on the ASX, with the bourse swinging wildly up and down...

Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase IIb trial to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC). The study...

The US health sector shows signs of stabilising as chaos subsides Immutep will meet with the FDA following “excellent” follow-on trial results When it comes to its sagging share price, Immuron leaves blame-shifting to the defeated Liberals...

The All Ordinaries Index (ASX: XAO) is down 0.3% today, but don't blame this surging ASX All Ords share. The soaring stock in question is clinical-stage biotech company Immutep Ltd (ASX: IMM). Immutep shares closed on Friday at 27 cents ap...

Highlights S&P/ASX 200 and All Ordinaries lift following Wall Street momentum New World Resources Ltd (ASX:NWC) and Pioneer Lithium Ltd (ASX:PLN) report progress in resource exploration Immutep Ltd (ASX:IMM) reveals new...

The ASX200 is set to open nearly a third of a percent higher today (0.27%) echoing Wall Street’s positive end to the week, driven by a strong jobs report and indications that trade tensions might be easing. Listen to the HotCopper podcas...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Immutep Ltd (ASX:IMM) has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer trial – the final stage of clinical study before the company eventually takes final efficacy results to regulators. Listen to the HotCo...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

  Percheron has detailed why its Duchenne muscular dystrophy trial flopped – and why it needs to find a new drug candidate Imugene’s multiple oncology and inflammation programs aren’t helping its valuation Impedimed and Micro-X raise funds...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

Immutep, Percheron and PYC feature in clinical trial updates Control Bionics guides to higher revenue, despite ongoing NDIS delays Botanix dispatches its first US prescriptions for its anti-sweat remedy   The year is ending with a bang ra...

Immutep Ltd (ASX:IMM) has reported a small-scale conceptual safety test among 49 patients using flagship drug IMP761 has seen no adverse effects. Despite this, shares were down nearly -3% after twenty minutes of Tuesday trade. The data r...